안구 통증 : 신규 요법, 미충족 수요 및 TPP 인사이트 보고서(2026년)

Eye Pain Emerging Therapy and TPP Insights

Thelansis's "Eye Pain Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Eye Pain Overview

Eye pain is a complex, non-specific clinical symptom rather than a distinct disease entity, arising from the noxious stimulation of ophthalmic trigeminal pathways due to corneal surface damage, intraocular inflammation, or elevated pressure. Key manifestations range from photophobia and epiphora to referred neuropathic dysesthesia. Diagnosis requires distinguishing distinct ocular pathologies via slit-lamp biomicroscopy, tonometry to measure intraocular pressure (IOP), and fluorescein staining to map epithelial defects. Rather than utilizing a generic triage approach, modern ophthalmic pharmacology targets the exact molecular drivers of the pain. Severe surface-level corneal pain linked to nerve degradation is managed with Oxervate (cenegermin-bkbj), a recombinant human nerve growth factor that restores sensory innervation. Conversely, intraocular inflammatory pain from uveitis utilizes targeted corticosteroid implants or anti-TNF biologics, while hypertensive optic nerve pain mandates aggressive IOP-lowering regimens, including sustained-release implants like iDose TR (travoprost). For deeper autoimmune-driven orbital pain, such as in thyroid eye disease, management has pivoted toward the newly approved IGF-1R inhibitor Lumvoa (veligrotug-vvze). Prognosis depends entirely on the underlying etiology; rapid, target-specific molecular intervention is critical to preventing permanent visual loss.

Key Highlights

• In France, females account for a larger share of the eye pain patient population (54.1%) compared with males (45.9%).
• Ocular surface disorders, infections, trauma, and inflammatory conditions remain major contributors to eye pain burden.
• Increasing healthcare utilization and ophthalmology consultations are supporting improved diagnosis and management.
• Chronic and recurrent ocular conditions continue to impact patient quality of life and productivity.
• Growing adoption of targeted ophthalmic therapies is improving symptom management outcomes.

Market Overview

• The France eye pain market is projected to grow from approximately $231.8 MN in 2025 to $323.0 MN by 2035.
• Market growth is supported by:
• Increasing prevalence of ocular surface and inflammatory eye disorders
• Growing utilization of prescription ophthalmic treatments
• Expansion of specialized eye care services is supporting treatment uptake.
• Future growth will depend on innovative anti-inflammatory and pain-targeted ophthalmic therapies.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Bausch & Lomb Incorporated
• Surface Ophthalmics, Inc.
• Biogen
• Oculis
• iRenix Medical, Inc.
• Frisch Medical Device Private Limited

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)